N/A
N=10
Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations
Asthma
Bottom Line
View on ClinicalTrials.gov: NCT01218399 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Aug 2017
Primary outcome: Primary: Percent Forced Expiratory Volume in One Second (FEV1) — 90; 88 % FEV1
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Symbicort (Drug)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Jul 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Forced Expiratory Volume in One Second (FEV1) |
90; 88 | — |
| SECONDARY Adverse Events |
0; 0 | — |
Summary
This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone.
Eligibility Criteria
Inclusion Criteria
Subjects will be considered for inclusion in this study based on meeting all of the following criteria:
- Male or female, aged 12 to 65 years
- Subjects with mild to moderate asthma as determined by NHLBI 2007 guidelines
- Subjects with exacerbation of their asthma symptoms by NHLBI 2007 guidelines
- IgE level at study entry less than 50 IU/mL
- Men and women of reproductive potential who document use of adequate contraception during the study and for 3 months after the conclusion of treatment with study drug/placebo
- Historical documentation of asthma in the patient's medical record. The patient should have 6 months or more of asthma medication and management by a Stanford physician.
- Women of childbearing potential who have a negative pregnancy test (urine or serum) at the time of study entry
- Subject's guardians who are capable of understanding the purpose and risks of the study and who sign a statement of informed consent for the study
Exclusion Criteria
Subjects will be ineligible for this study based on any one of the following criteria:
- With a chronic or acute disease that might interfere with the evaluation of Symbicort or Pulmicort Flexhaler therapy
- Pregnancy or lactation
- Current or prior malignancies (excluding non-melanoma skin carcinoma or carcinoma in situ of the cervix that has been adequately treated)
- History of infection with human immunodeficiency virus (HSC-1), hepatitis B virus (HBV), or hepatitis C virus (HCV); or Hepatitis A virus (HAV)
- Infections that require intravenous antibiotic therapy
- Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine >1.6 mg/dL; ALT or AST > 1.5x the upper limit of normal; history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to study entry)
- Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study entry
- Treatment with any investigational drugs or therapies within 2 weeks prior to study entry
- Any use of oral, systemic corticosteroids within 2 weeks prior to study entry
Data sourced from ClinicalTrials.gov (NCT01218399). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.